The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma with HER2-high Expression.
Voluntarily consent to participate in the study and sign the informed consent form
Expected survival period >12 weeks
ECOG Performance Status 0 or 1
Histologically confirmed unresectable locally advanced or metastatic --gastric/gastroesophageal junction adenocarcinoma
Presence of central nervous system (CNS) metastasis and/or carcinomatous meningitis
Peripheral neuropathy > Grade 1
Tumor lesions with a tendency to bleed
Severe gastrointestinal dysfunction that may affect drug intake, transport, or absorption